DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Desvenlafaxineis the generic ingredient in four branded drugs marketed by Alembic Pharms Ltd, Osmotica Pharm Corp, Sun Pharma Global, Teva Pharms Usa, Actavis Labs Fl, Casi Pharms Inc, Hikma, Intellipharmaceutics, Lupin Ltd, Mylan, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in fifteen NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.
There are sixteen drug master file entries for desvenlafaxine. Two suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for DESVENLAFAXINE
Recent Clinical Trials for DESVENLAFAXINE
Identify potential brand extensions & 505(b)(2) entrants
|H. Lundbeck A/S||Phase 4|
|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||Phase 3|
|Luye Pharma Group Ltd.||Phase 1|
Generic filers with tentative approvals for DESVENLAFAXINE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for DESVENLAFAXINE
|Drug Class||Serotonin and Norepinephrine Reuptake Inhibitor |
|Mechanism of Action||Norepinephrine Uptake Inhibitors |
Serotonin Uptake Inhibitors
Cytochrome P450 2D6 Inhibitors
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Pf Prism Cv||PRISTIQ||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||021992-003||Aug 20, 2014||AB||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|Lupin Ltd||DESVENLAFAXINE SUCCINATE||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||204172-001||Jun 29, 2015||AB||RX||No||No||Start Trial||Start Trial||Start Trial|
|Yichang Humanwell||DESVENLAFAXINE SUCCINATE||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||210014-002||Oct 1, 2018||AB||RX||No||No||Start Trial||Start Trial||Start Trial|
|Casi Pharms Inc||DESVENLAFAXINE SUCCINATE||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||204028-001||Jun 29, 2015||AB||RX||No||No||Start Trial||Start Trial||Start Trial|
|Sun Pharma Global||DESVENLAFAXINE||desvenlafaxine fumarate||TABLET, EXTENDED RELEASE;ORAL||205583-001||Jan 28, 2014||DISCN||Yes||No||Start Trial||Start Trial||Start Trial|
|Pf Prism Cv||PRISTIQ||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||021992-001||Feb 29, 2008||AB||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.